| CD133+ |
Increased tumorigenic efficiency (cell lines, |
Baba(65), |
|
primary tumor, ascites, xenograft tumor) |
Curley(66) |
|
Enhanced vasculogenesis (cell lines, primary |
Kusumbe(67), |
|
tumor, ascites, xenograft tumor) |
Silva(27) |
| CD44+/MyD88+ |
Increased tumorigenesis; spheroid formation; chemoresistance (ascites, cell lines) |
Alvero(68) |
| CD44+/CD117+ |
Increased tumorigenesis; chemoresistance (primary tumor, xenograft tumors) |
Zhang(69) |
| CD44+/CD24- |
Spheroid formation; recapitulate parental tumor (cell lines) |
Shi(70) |
| CD44+/CD24+ |
Increased tumorigenesis (primary tumor, xenograft tumor) |
Gao(71) |
| ALDH1A1+ |
Increased tumorigenesis; pluripotency (cell lines) |
Landen(26) |
| ALDH1A1+/CD133+ |
Increased tumorigenesis; chemoresistance (cell |
Silva(27) |
|
lines, primary tumor, xenograft tumor) |
Kryczek(72) |
|
Increased tumorigenesis; self-renewal (primary |
|
|
tumor) |
|
| ABCG2 (Side pop'n) |
Increased tumorigenesis (cell lines (murine and human), ascites) |
Szotek(36) |
|
Increased tumorigenesis; chemoresistance (cell lines, ascites, xengraft tumor) |
Hu(73) |
|
Increased tumorigenesis; chemoresistance; self-renewal (cell lines, xenograft tumor) |
Dou(74) |
|
Chemoresistance (cell lines) |
Kobayashi(61) |
